The article discusses a guideline for hepatitis C virus (HCV) drugs published by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America in 2014. Topics covered include the estimated number of individuals in the U.S. with chronic hepatitis C infection, the effectiveness of sofosbuvir in treating HCV infections, and the cost-effectiveness of newer HCV therapies.